Document is current

Any future updates will be listed below

Correction: Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis

Crossref DOI link: https://doi.org/10.1186/s12885-024-12249-y

Published Online: 2024-04-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark